Nielka van Erp' s research activities lie in the field of the pharmacology of targeted oncolytics and the use of pharmacology to individualize and optimize cancer treatment. Her interest in the pharmacology of this relatively new group of drugs in oncology originates from her PhD in which she investigated the pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. She was trained as a Hospital Pharmacist at the Leiden University Medical Center (LUMC) where she also obtained her PhD degree (2009). She continued her work in the LUMC as a post doc researcher/hospital pharmacist. In 2011 she started her career in the Radboud University Medical Center, focusing on a novel research line entitled " pharmacology of oncolytics" . Her research concentrates on dose personalization strategies by investigating and understanding the pharmacokinetic/ pharmacodynamic behavior of targeted oncolytic drugs used for solid tumors. She is the (principle)-investigators of multiple projects that aim to narrow the gap between treatment onset and response evaluation as well approaches to dose optimize the currently used oncolytica therapy.
Ideally, every procedure in clinical practice and public health should take place based on proof, instead of intuition or 'experience'. Our aim is to innovate and personalize healthcare and public health.